Risedronate

Publisher Website
Google Scholar
Abstract
▲ Risedronate is a pyridinyl bisphosphonate that can be administered orally in lower dosages than other antiresorptive bisphosphonates. Like others of its class risedronate inhibits osteoclast-mediated bone resorption. ▲ In experimental models of osteoporosis, risedronate inhibited bone loss and improved trabecular architecture. ▲ In patients with Paget’s disease, pain diminished or disappeared and serum alkaline phosphatase levels decreased after treatment with oral risedronate 30 mg/day for ≤3 months. ▲ Risedronate 30 mg/day orally for 2 months significantly reduced pain, whereas etidronate 400 mg/day orally for 6 months tended to reduce pain, in a randomised double-blind trial of patients with Paget’s disease. ▲ Oral risedronate 5 mg/day for ≤2 years increased bone mass in postmenopausal women with low or normal bone mass. Risedronate 2.5 mg/day prevented bone loss in postmenopausal women treated with glucocorticoids for rheumatoid arthritis. ▲ The incidence of gastrointestinal or other adverse events was similar in patients treated with risedronate or placebo in clinical trials.